Current opinion on treatment of inflammatory bowel disease in pregnant women

Archives of Medical Science

Volumn 8, Issue 6, 2012, Pages 983-986

  Salari, Pooneh ^a   Nikfar, Shekoufeh ^b,c   Abdollahi, Mohammad ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AMPICILLIN; BUDESONIDE; CEPHALOSPORIN; CIPROFLOXACIN; CYCLOSPORIN; ERYTHROMYCIN; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; PREDNISOLONE; PROBIOTIC AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

BIOLOGICAL THERAPY; CONGENITAL MALFORMATION; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG SAFETY; ENTERITIS; FETUS OUTCOME; GROWTH RETARDATION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREGNANT WOMAN; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SUPPLEMENTATION; TREATMENT PLANNING;

EID: 84873107346     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.32403     Document Type: Review

References (40)

1. Salari-Sharif P, Abdollahi M. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a compre hensive review. Curr Pharm Des 2010;16:3661-7.
2. Moleski SM, Choudhary C. Special considerations for women with IBD. Gastroenterol Clin N Am 2011;40:387-98.
3. Mountifield RE, Prosser R, Bampton P, Muller K, Andrews JM. Pregnancy and IBD treatment: this challenging interplay from a patients' perspective. J Crohns Colitis 2010;4:176-82.
4. Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep 2009;11:395-9.
5. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Alim Pharmacol Ther 2011;34:724-34.
6. Van Der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010;4:493-510.
7. Vermeire S, Carbonnel F, Coulie PG, et al. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis 2012;6:811-23.
8. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008;53:2524-31.
9. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008;4:185-90.
10. Cassina M, Fabris L, Okolicsanyi L, et al. Therapy of inflammatory bowel diseases in pregnancy and lac tation. Expert Opin Drug Saf 2009;8:695-707.
11. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009;54:712-21.
12. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54:1157-70.
13. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a metaanalysis. Reprod Toxicol 2008;25:271-5.
14. Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with IBD treated during pregnancy with oral mesalazine microgrannules. Alim Pharmacol Ther 1998;12:1101-8. (Pubitemid 28508723)
15. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalazine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23-8. (Pubitemid 28020950)
16. Correia LM, Bonilha DQ, Ramos JD, Ambrogini O, Miszputen SJ. Treatment of inflammatory bowel disease and pregnancy: a review of the literature. Arq Gastroenterol 2010;47:197-201.
17. Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohns disease during pregnancy. Inflamm Bowel Dis 2009;15:25-8.
18. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92.
19. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17. (Pubitemid 36055333)
20. Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004;99:656-61. (Pubitemid 38607969)
21. No/rga°rd B, Pdersen L, Christensen LA, So/rensen HT. Therapeutic drug use in women with Crohns disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007;102:1406-13. (Pubitemid 46976292)
22. Cleary BJ, Källén B. Early pregnancy azathiopurine use and pregnancy outcomes. Birth Defects Res 2009;85:647-54.
23. Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathiopurine on birth outcomes in women with inflammatory owel disease (IBD). J Crohn Colitis 2011;5:234-8.
24. Dozois EJ, Wolff BG, Tremaine WJ, et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis Colon Rectum 2006;49:64-73. (Pubitemid 41830657)
25. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastro entero logists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009;104:228-33.
26. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohns disease. Am J Gastroenterol 2001;96:2274-75. (Pubitemid 32660942)
27. ÓDonnell S, ÓMorain C. Use of antitumor necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Alim Pharmacol Ther 2008;27:885-94. (Pubitemid 351551987)
28. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohns disease. Aliment Pharmacol Ther 2005;21:733-8. (Pubitemid 40469001)
29. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 2004;270:79-85. (Pubitemid 39208317)
30. Subhani JM, Hamiliton MI. The management of inflammatory bowel disease during pregnancy. Alim Pharmacol Ther 1998;12:1039-53. (Pubitemid 28508718)
31. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohns disease in pregnancy. Inflamm Boel Dis 2006;12:827-8. (Pubitemid 44253768)
32. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54.
33. Zelinkova Z, De Haar C, De Ridder L, et al. High intrauterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053-8.
34. Van Assache G, Lewis JD, Lichtenstein GR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohns and Colitis Organization: safety. Am J Gastroenterol 2011;106:1594-602.
35. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010;6:49-55.
36. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol 2011;17:2696-701.
37. Hosseini A, Nikfar S, Abdollahi M. Are probiotics effective in management of irritable bowel syndrome? Arch Med Sci 2012;8:403-5.
38. Elias J, Bozzo P, Einarson A. Are probiotics safe for use during pregnancy and lactation? Can Fam Physician 2011;57:299-301.
39. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14:1736-50.
40. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 2011;7:1000-12.